Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

NCT01585038 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Cardiovascular Disease

Interventions

DRUG: Efavirenz
DRUG: Rilpivirine

Sponsor

Indiana University

Collaborators

[object Object]